ZLAB (Zai Lab) Marketable Securities: $10.0 Mil (As of Mar. 2026)


ZLAB Zai Lab Ltd ZLAB
64 GF Score
Price $18.00
GF Value $30.30
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Zai Lab Marketable Securities?

Zai Lab ZLAB -2.81% 64 Marketable Securities is $10.0 Mil as of Mar. 2026. GuruFocus rates ZLAB with a GF Score™ of 64/100 and a GF Value™ of $30.30 (Possible Value Trap). The stock has 8 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Zai Lab's Marketable Securities for the quarter that ended in Mar. 2026 was $10.0 Mil.

Zai Lab's annual Marketable Securities increased from Dec. 2023 ($16.3 Mil) to Dec. 2024 ($330.0 Mil) but then declined from Dec. 2024 ($330.0 Mil) to Dec. 2025 ($10.0 Mil).

Zai Lab  (NAS:ZLAB) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Zai Lab Marketable Securities Related Terms

Zai Lab Marketable Securities Historical Data

* Premium members only.

The historical data trend for Zai Lab's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zai Lab Marketable Securities Chart

Zai Lab Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 445.00 0.00 16.30 330.00 10.00

Zai Lab Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 10.00 10.00
ZLAB
64GF Score
Zai Lab Ltd ZLAB
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zai Lab Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $10.0 Mil mean?
Zai Lab (ZLAB) has a Marketable Securities of $10.0 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Zai Lab and its competitors.
Is Zai Lab's Marketable Securities too high?
Zai Lab's current Marketable Securities is $10.0 Mil. Overall, Zai Lab has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's Marketable Securities compare to TYRA and TRVI?
Zai Lab's Marketable Securities of $10.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Zai Lab and its competitors. Zai Lab's current Marketable Securities is $10.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (ZLAB) is currently considered Possible Value Trap. The stock's GF Value™ is $30.30, compared to a current price of $18.00 — trading 40.6% below its estimated fair value. The current Marketable Securities is $10.0 Mil. Zai Lab's overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Zai Lab (ZLAB), the current Marketable Securities is $10.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zai Lab (ZLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued. The current stock price of $18.00 is trading 40.6% below its estimated GF Value™ of $30.30. GuruFocus considers Zai Lab to be Possible Value Trap.

Key valuation signals for ZLAB:

  • Marketable Securities: $10.0 Mil
  • GF Value™: $30.30 vs. price of $18.00 (40.6% below fair value)
  • GF Score™: 64/100 with 8 warning signs

No single metric tells the full story. See the ZLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zai Lab Business Description

Other Exchanges 09688:Hong Kong1ZLB:Germany
Address 899 Halei Road, Building B, Pudong, Shanghai, CHN, 201203
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
64GF Score

Get the complete analysis for ZLAB

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.00
Price
$30.30
GF Value